Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months. The characteristics of mammary tumor induction in the control and experimental groups did not differ until the age of 9 months. Later on, Epitalon-treated mice revealed distinct inhibition of carcinogenesis. One tumor per animal was detected in 7% (control), 4% (Vilon) and 16% (Epitalon) (p <0.05). Two or more tumors per animal were in 75%, 95% and 56%, respectively (p <0.05). Largest diameter of mammary adenocarcinoma in the Epitalon group was smaller than in controls by 33% (p <0.05). Although the number of mice with metastases to the lung in all three groups was practically identical, their incidence in the Vilon group was 2.6 times higher than in Epitalon-treated animals (p <0.05). Largest diameter of metastasis in the Epitalon group was the smallest, too. Our data point to inhibition of mammary carcinogenesis by Epitalon in transgenic erbB-2/neu mice.
|Translated title of the contribution||Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice|
|Number of pages||4|
|Publication status||Published - 2002|
ASJC Scopus subject areas